Replies to post #244271 on Biotech Values

[DewDiligence]

PCVX strikes while the iron is hot:

https://www.globenewswire.com/news-release/2022/10/24/2540337/0/en/Vaxcyte-Announces-Commencement-of-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

The size of the offering has not yet been determined.

[DewDiligence]

PCVX gets BTD for VAX-24 in adult market—investors yawn:

https://www.globenewswire.com/news-release/2023/01/05/2583736/0/en/Vaxcyte-s-VAX-24-Granted-FDA-Breakthrough-Therapy-Designation-for-the-Prevention-of-Invasive-Pneumococcal-Disease-in-Adults.html

[DewDiligence]

PCVX +16% on phase-2 data for VAX-24:

https://finance.yahoo.com/news/vaxcyte-reports-positive-data-phase-103000816.html

https://investors.vaxcyte.com/static-files/90fd9df6-3990-4954-acd8-8e24690783a0

VAX-24 is a 24-valent-pneumococcal vaccine.

Please see #msg-170872992 and #msg-170868559 for background info.